Is Axsome Therapeutics, Inc. AXSM stock Halal to invest in?

Yes, as of September 2026, Axsome Therapeutics, Inc. stock (AXSM) is classified as a Shariah compliant stock. Tabadulat applies AAOIFI Shariah Standard No. 21, issued by the Accounting and Auditing Organization for Islamic Financial Institutions, screening non-permissible income first and then the two interest-based ratios and the capital structure. On the latest data, Axsome Therapeutics, Inc. passes on every count: non-permissible income under 5% of revenue, interest-bearing debt and investments each under 30% of market capitalisation, and no preference share issue. The stock's current purification factor is 99.25%. Compliance is reassessed every month as updated screening data arrives, and a stock's status can change when new financial reports are released. You can always check the current status of Axsome Therapeutics, Inc. and explore other Shariah compliant stocks in the Tabadulat app.

How often is Axsome Therapeutics, Inc. AXSM reviewed for Shariah compliance?

Tabadulat reviews Axsome Therapeutics, Inc. AXSM for Shariah compliance every month. Each review applies the AAOIFI Shariah Standard No. 21 methodology, screening the company's business activities, non-permissible income, interest-bearing investments, interest-bearing debt, and preference shares, against the company's latest available financial data. The process operates under the direct supervision of Tabadulat's dedicated Shariah Supervisory Board of Islamic finance scholars. Because compliance depends on financial ratios that move with market capitalisation and reported results, a stock's status can change from one review to the next. Monthly screening ensures the status shown for Axsome Therapeutics, Inc. reflects current financial data rather than an outdated assessment, and Tabadulat app users are notified if a holding in their portfolio becomes non-compliant.

Does Axsome Therapeutics, Inc. AXSM pass the AAOIFI Non Permissible Income criteria?

Yes, as of September 2026, Axsome Therapeutics, Inc. stock (AXSM) passes the AAOIFI non-permissible income screen. Under AAOIFI Shariah Standard No. 21, income from impermissible sources (such as interest or Riba, conventional financial services, alcohol, gambling, or tobacco) must remain below 5% of a company's total revenue. Axsome Therapeutics, Inc.'s income from non-permissible sources is currently within this 5% threshold. Even permissible levels of incidental impure income should still be purified: investors donate the corresponding share of dividends to charity, as reflected in the stock's purification factor. This screen is reassessed monthly using the company's latest financial disclosures.

Does Axsome Therapeutics, Inc. AXSM pass the AAOIFI Interest Bearing Investments criteria?

Yes, as of September 2026, Axsome Therapeutics, Inc. stock (AXSM) passes the AAOIFI interest-bearing investments screen. Each month Tabadulat compares Axsome Therapeutics, Inc.'s holdings in interest-earning instruments, such as conventional deposits, bonds and treasury bills, against AAOIFI's 30% market capitalisation cap. The current screening shows the company inside the limit. Because the ratio is measured against market capitalisation, it can move with the share price as well as the balance sheet, which is why Tabadulat rescreens the stock every month.

Does Axsome Therapeutics, Inc. AXSM pass the AAOIFI Interest Bearing Debt criteria?

Yes, as of September 2026, Axsome Therapeutics, Inc. stock (AXSM) passes the AAOIFI interest-bearing debt screen. AAOIFI tolerates some conventional borrowing but draws the line at 30% of market capitalisation. On the latest data, Axsome Therapeutics, Inc.'s interest-bearing debt stays below the line. Because market capitalisation changes daily, a company's debt ratio can drift toward or away from the limit even without new borrowing, which is why this screen is reassessed every month.

What is the dividend purification factor for Axsome Therapeutics, Inc. AXSM stock?

The dividend purification factor for Axsome Therapeutics, Inc. (AXSM) stands at 99.25% in the September 2026 screening. In plain terms, 99.25% of a AXSM dividend is retained, and the remainder reflects incidental non-permissible income, typically interest on corporate cash, which Halal investors donate to charity (Tazkiyah). AAOIFI methodology asks for purification even on fully compliant stocks. The factor is recalculated with each monthly screening as new financial data arrives, and the Tabadulat app can help you calculate and track purification across your whole portfolio.

Does Axsome Therapeutics, Inc. AXSM pass the AAOIFI Preference Share screen?

Yes, as of September 2026, Axsome Therapeutics, Inc. stock (AXSM) passes the AAOIFI preference share screen. AAOIFI Shariah Standard No. 21 prohibits investing in preference shares because they grant holders guaranteed or priority rights to dividends and capital ahead of ordinary shareholders, a structure that conflicts with the Shariah principle that investors should share profit and loss in proportion to their ownership. Axsome Therapeutics, Inc. has no impermissible preference share structure affecting its ordinary shares, so the stock is compliant on this criterion. Like all AAOIFI screens, this is verified in each monthly review.

Invest Halal, Anytime, Anywhere

Download the Tabadulat app and start building your Shariah-compliant portfolio in minutes.

English

العربية

Is Axsome Therapeutics (AXSM) stock Halal?

NASDAQ

Shariah-Compliant

Not Shariah

September 2026 AAOIFI screening result for Axsome Therapeutics, Inc. (AXSM): non-permissible income, pass. Interest-bearing investments, pass. Interest-bearing debt, pass. Preference shares, pass. Dividend purification factor: 99.25%. Re-screened monthly against AAOIFI Shariah Standard No. 21.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

816

Website:

https://www.axsome.com

Market cap:

$11.0B

P/E ratio:

Dividend yield:

52-week range:

$112.90 - $260.19

Data as of:

3 September 2026

Screening history:

September 2026: PASS

Axsome Therapeutics is a commercial-stage biopharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The company focuses on addressing medical conditions with significant unmet needs, offering treatments where existing options are limited or inadequate. Among its key marketed products are Auvelity, an oral medication for major depressive disorder, and Sunosi, for managing excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Before any of that matters to a Muslim investor, one question comes first: is Axsome Therapeutics stock Halal?

Is Axsome Therapeutics Shariah compliant?

The Shariah case on a technology company like Axsome Therapeutics is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Axsome Therapeutics pass the business activity test?

Yes. In the September 2026 screening Axsome Therapeutics holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Axsome Therapeutics' income Halal?

Yes, within AAOIFI's tolerance. Axsome Therapeutics' income from non-permissible sources stays below 5% of revenue in the September 2026 screening, and the small impure portion is handled through purification: the factor of 99.25% tells holders of AXSM what share of each dividend to keep and what remainder to donate to charity.

Does Axsome Therapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation. Because the caps move with the share price, our Shariah Supervisory Board has AXSM re-screened every month, and the result above always shows the latest verdict.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the four screens? Read Why a Halal Stock Screener Matters for Halal Investing

Frequently asked questions

Related stocks

Mobile login screen for Tabadulat with fields to enter email, a Continue button, an option to create an account, and a language selector showing EN.

Step 1

Open your account.

Create your Tabadulat account in minutes: enter your details, complete identity verification, and add funds by secure transfer in multiple currencies. You're ready to start investing in Halal stocks the same day.

Mobile screen showing add money interface with 100 AED amount and Manual Bank Transfer payment method selected, noting 1-2 business days processing.

Step 2

Deposit.

Add funds to your account using a secure payment method. You can deposit in multiple currencies to get started.

Step 3

Screen.

Screen Stocks for Free and explore a wide range of stocks that are ethically screened for Shariah compliance. Use our Halal Stock Screener to find the best opportunities.